Moldova Receives Over $7 Mil in Medical Supplies for Ukrainian Refugees: In Partnership With Flexport.org, Airlink, World Hope International, Lift Non-Profit Logistics and Globus Relief

Moldova:

Following a request for medical supplies from the Moldovan authorities, World Hope International (WHI), Lift Non-Profit Logistics, Globus Relief, Airlink, and Flexport.org partnered to provide humanitarian relief for more than 300,000 Ukrainian refugees currently seeking safety and protection in the border country of Moldova.

The partnership provided over 220,000 pounds of medical supplies valued at over $7 million, to serve a specifically requested need from the Moldova Ministry of Health. With the support of Flexport.org, air carrier Atlas Air, and cargo handler Alliance Ground International, these supplies have been moved from Utah and airlifted via a Boeing 747 from Chicago to Amsterdam, where Flexport.org then arranged for trucking partners to transport the cargo to Moldova. Fulfilling the Moldovan authorities request for assistance required multi-faceted project coordination and experience managing complex supply chains. This relief effort demanded specialized skills to source the requested supplies and transport them from Utah to Moldova via Chicago and Amsterdam.

“In these difficult times, Moldova is helping Ukrainian refugees with needed shelter and assistance. Given this context, we are highly appreciative of the efforts our American friends have put towards gathering an impressive amount of medical supplies. This support will be used and distributed by the Ministry of Health for the Ukrainian refugees in Moldova, and we are so thankful for it,” said Moldova’s Ambassador to the U.S., Eugen Caras.

CEO of WHI, John Lyon, adds, “The events unfolding in Ukraine and the escalating violence across the region is beyond tragic on many levels – and is quickly becoming one of the largest refugee events of our lifetime. While we are looking at ways to scale up our support, we hope this week’s effort will make a large impact on those who receive these critical supplies.”

“Humanitarian responses are incredibly complex and demand a wide range of coordination from nonprofits. By providing strong airfreight solutions and funding support, we aim to help our nonprofit partners focus on what they do best and respond immediately when disaster strikes,” said Susy Schöneberg, Head of Flexport.org.

“Airlink is delighted to be part of this coalition of organizations using their resources and expertise to deliver humanitarian aid to Moldova in support of Ukrainian refugees,” said Steven J. Smith, Airlink President and CEO. “There are considerable and growing supply chain difficulties in the region, so partnership and coordination are vital to ensuring Ukrainian refugees get the aid they need.”

Shaimaa Al Wassiti, President, Globus Relief Humanitarian adds, “Globus Relief is equipped to supply needs for all forms of medical care. This initial shipment includes more immediately needed items such as bandages, syringes, IVs, and any sort of emergency supplies that are used in first response medical care.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy